ARIScience
ARIScience is at the forefront of drug discovery, leveraging a unique combination of AI, quantum chemistry, computer vision, and biochemistry to develop novel small molecule drugs. Their mission is to reduce the burden of human disease by discovering therapeutics that interrupt disease pathways. With a focus on neurodegenerative, inflammatory, and infectious diseases, ARIScience employs cutting-edge in silico methods to efficiently identify and optimize drug candidates. Their commitment to innovation and collaboration with leading institutions positions them to make a significant impact on human health. ARIScience is creating value in two ways: Value 1: ARIScience is developing small molecule assets targeting respiratory depression, cutaneous burn and radiation injuries, antivirals for EBOV and DENV, bacteriostatic antibiotic targeting Staph aureus. Value 2: It's novel AI driven quasi quantum chemistry (AI+QQ) small molecule discovery platform for precision protein inhibition and potentiation.
Industries
Nr. of Employees
small (1-50)
ARIScience is currently seeking investment
ARIScience is seeking a series-a investment in the range of 1m-5m
Products
Computational drug‑discovery platform
An integrated computational platform that supports AI models, quasi‑quantum calculations, and workflows for designing and prioritizing small‑molecule candidates.
Biological test‑data integration platform
A technology asset for integrating bioassay data and supporting the interface between computational predictions and wet‑lab validation workflows.
Computational drug‑discovery platform
An integrated computational platform that supports AI models, quasi‑quantum calculations, and workflows for designing and prioritizing small‑molecule candidates.
Biological test‑data integration platform
A technology asset for integrating bioassay data and supporting the interface between computational predictions and wet‑lab validation workflows.
Expertise Areas
- AI‑driven drug design
- Quantum chemistry for molecular modeling
- In‑silico to in‑vitro translation
- Preclinical in vivo studies (small animal models)
Key Technologies
- AI‑driven molecular design
- Quasi‑quantum calculations / quantum chemistry
- Computer vision for molecular analysis
- In‑silico simulation and modeling
Key People
Clinical Research Expert, Global Health Expert
Acute Care Expert
Clinical Care Expert Hospitalist
In-vitro Assay Expert
Clinical Research Expert, Global Health Expert
Acute Care Expert
Clinical Care Expert Hospitalist
In-vitro Assay Expert
News & Updates
ARIScience presented their OIRD countermeasure results at the NIH/NIDA/BARDA conference on December 18, 2024.
In April 2023, ARIScience was awarded an advanced protein impact via small molecule research contract by the United States Biomedical Advanced Research and Development Agency, successfully completed in October 2024.
ARIScience presented their OIRD countermeasure results at the NIH/NIDA/BARDA conference on December 18, 2024.
In April 2023, ARIScience was awarded an advanced protein impact via small molecule research contract by the United States Biomedical Advanced Research and Development Agency, successfully completed in October 2024.